Spravato FAQs: Eligibility, Cost, Side Effects & Treatment in Frisco, TX

Spravato may be considered for certain adults with major depressive disorder, including adults with treatment-resistant depression (TRD).

Qualification is not based on one symptom or medication alone. A clinician reviews your diagnosis, severity of depression, previous antidepressant treatments, response to those treatments, current medications, medical history, and potential safety concerns.

Insurance plans may also have their own medical-necessity and prior-authorization requirements.

The most reliable way to determine whether Spravato may be appropriate for you is through an individualized clinical evaluation.

Treatment-resistant depression is generally associated with an inadequate response to at least two appropriate antidepressant treatment trials.

However, clinical eligibility and insurance coverage are not always identical. Insurers may specify which medications count, how long they must have been taken, the dose used, whether augmentation treatments were attempted, and what documentation is required.

At Wholesome Clinic, we review your previous medication history, dose, duration, effectiveness, tolerability, and available records before determining the appropriate next step.

Treatment-resistant depression, often called TRD, generally refers to major depressive disorder that has not improved adequately despite appropriate antidepressant treatment.

Before identifying depression as treatment resistant, a clinician may review whether previous medications were taken at adequate doses and durations, whether the diagnosis remains accurate, whether another psychiatric or medical condition could be affecting symptoms, and whether treatment adherence or tolerability influenced the outcome.

TRD does not mean that no treatment can help. It means that a different treatment strategy may need to be considered.

Spravato (esketamine) is an FDA-approved prescription nasal spray used to treat certain adults with depression.

For adults with treatment-resistant depression, Spravato may be used either by itself or together with an oral antidepressant.

Spravato also has an FDA-approved indication, together with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior.

Spravato has not been shown to prevent suicide or to eliminate the need for hospitalization when hospitalization is clinically necessary.

Not necessarily for treatment-resistant depression. Current FDA labeling allows Spravato to be used for adult TRD either as monotherapy or together with an oral antidepressant.

Your clinician will review your current treatment, previous responses, side effects, diagnosis, and overall clinical needs before recommending whether an oral antidepressant should remain part of your treatment plan.

Spravato is not appropriate for everyone.

It is contraindicated in certain patients for whom an increase in blood pressure or intracranial pressure would pose a serious risk, including people with certain aneurysmal vascular disorders, arteriovenous malformations, or a history of intracerebral hemorrhage. It is also contraindicated in patients with hypersensitivity to esketamine, ketamine, or ingredients in the product.

Other medical conditions, blood-pressure concerns, pregnancy, medication interactions, substance-use history, and psychiatric factors may require additional evaluation before treatment.

Eligibility is determined individually after reviewing your medical and psychiatric history.

Yes, in many cases psychotherapy can continue while you receive Spravato.

Therapy, psychiatric medication management, lifestyle interventions, and Spravato can each play different roles in a comprehensive depression treatment plan.

Your clinician can help coordinate the overall treatment approach based on your symptoms, goals, and existing care team.

No. Spravato contains esketamine, which is related to ketamine but is not the same medication.

Ketamine contains two mirror-image forms of the molecule, while esketamine contains one of those forms. Spravato is specifically formulated as a nasal spray and is FDA approved for particular depression indications.

Spravato must be administered under healthcare supervision through the required safety program. IV ketamine treatment follows a different regulatory and clinical framework.

Some patients may experience improvement early in treatment, but response varies and Spravato should not be judged from one treatment session alone.

In clinical research involving adults with treatment-resistant depression, differences in depressive symptoms were observed as early as approximately 24 hours, with treatment benefit evaluated over the four-week induction phase.

Some people improve sooner than others, and some do not respond adequately. Your clinician will monitor symptoms over time rather than relying on how you feel immediately after one dose.

For treatment-resistant depression, Spravato is usually given more frequently at the beginning and then reduced to a maintenance schedule.

The goal is to use the lowest treatment frequency that maintains therapeutic benefit. Your schedule may be adjusted according to response and tolerability.

There is no single treatment duration that applies to every patient with treatment-resistant depression.

After the initial four-week treatment period, your clinician evaluates whether you are benefiting enough to continue. Longer-term treatment is individualized based on symptom improvement, relapse risk, tolerability, functioning, and overall treatment goals.

Some patients continue maintenance treatment for an extended period, while others may require a different strategy.

No. Spravato is not a take-home medication.

Patients self-administer the nasal spray in an approved healthcare setting under the direct supervision of a healthcare professional. You then remain under observation because temporary sedation, dissociation, blood-pressure changes, respiratory effects, and other reactions can occur.

A Spravato session includes pre-treatment assessment, supervised self-administration of the nasal spray, and a required observation period.

Your healthcare team will review how you are feeling and assess appropriate safety measures before dosing. You self-administer the prescribed Spravato dose using the nasal-spray devices while supervised.

During the monitoring period, the care team assesses your clinical status, including blood pressure and other safety measures as appropriate. You remain in the clinic until the required monitoring period is complete and the healthcare professional determines that you are clinically stable to leave.

You must be monitored for at least two hours after Spravato administration.

Some people may need to remain longer if symptoms, blood pressure, sedation, or other clinical concerns have not resolved enough for safe discharge.

Your total appointment time will therefore be longer than the medication-administration portion alone.

Spravato can temporarily impair alertness, judgment, coordination, and reaction time.

Even if you feel better before leaving the clinic, you should not drive, operate machinery, or perform activities requiring full mental alertness until the next day after a restful sleep.

Yes. You need reliable transportation home after every Spravato treatment.

You cannot drive yourself after treatment. Please arrange transportation before your appointment according to the clinic's transportation policy.

Wholesome Clinic may be able to offer limited transportation assistance for eligible patients when needed for treatment safety. Availability is limited and must be arranged with the clinic in advance.

Patients should generally plan the remainder of the treatment day around recovery rather than demanding work, school, driving, or other safety-sensitive activities.

Sedation, dizziness, dissociation, fatigue, and impaired concentration can occur. You should not drive or operate machinery until the next day after a restful sleep.

Your clinic will give you individualized preparation instructions. To reduce the likelihood of nausea and vomiting, patients are generally instructed to avoid food for at least two hours before treatment and liquids for at least 30 minutes before treatment.

Tell your clinician about all prescription medications, over-the-counter products, supplements, alcohol or substance use, and any change in your health before treatment.

Certain medications may require special consideration, but do not stop a prescribed medication unless your healthcare professional instructs you to do so.

Bring any information requested by your care team and confirm your transportation arrangements before treatment.

Because you will spend at least two hours under observation, many patients also bring headphones, quiet music, a comfortable layer, or another low-stimulation activity.

Common effects during treatment can include dissociation, dizziness, nausea, sedation or sleepiness, vertigo, reduced sensation, anxiety, lethargy, increased blood pressure, vomiting, a feeling of intoxication, and headache.

Effects vary from person to person and are one reason Spravato must be administered with healthcare supervision and post-dose observation.

The experience varies considerably.

Some patients describe dizziness, sleepiness, altered perception, feeling detached or “spaced out,” changes in sensory experience, nausea, or a floating sensation. Others experience relatively mild effects.

These experiences are monitored during treatment and generally lessen during the observation period.

Yes. Spravato can temporarily increase blood pressure.

Blood pressure is assessed before treatment and again after dosing, including at approximately 40 minutes when the medication's blood-pressure effect commonly peaks. Additional monitoring is performed as clinically indicated.

Certain cardiovascular or cerebrovascular conditions require careful assessment, and Spravato should not be administered when an increase in blood pressure or intracranial pressure would pose a serious risk.

Tell your care team immediately.

These effects can occur during Spravato treatment and are one reason you remain under direct observation. The healthcare team will assess your symptoms, monitor your clinical status, and provide appropriate support.

How you tolerate each treatment also helps inform future dosing and treatment planning.

Spravato is a Schedule III controlled substance and has potential for abuse and misuse.

For this reason, your clinician reviews substance-use history and other risk factors before treatment. Spravato is administered only under healthcare supervision and is subject to the SPRAVATO REMS safety program.

Patients with a history of substance-use disorder may require additional assessment and monitoring; a history of substance use does not automatically answer the eligibility question by itself.

Many commercial health plans and government insurance plans provide Spravato coverage when their medical-necessity criteria are met, but coverage varies.

Most plans require prior authorization before treatment. Your deductible, copay, coinsurance, pharmacy benefit, medical benefit, treatment-site network status, and other plan provisions can affect your actual out-of-pocket cost.

Wholesome Clinic can assist with benefits verification and the authorization process for patients receiving treatment through our Frisco Spravato program.

Requirements vary by insurance plan.

A payer may request documentation of your diagnosis, previous antidepressant trials, dose and treatment duration, inadequate response or intolerance, current treatment plan, and other clinical information.

Some plans may have additional step-therapy, network, specialty pharmacy, or authorization requirements.

We review your specific benefits rather than assuming that one insurer's requirements apply to every patient.

There is no single out-of-pocket price that applies to every insured Spravato patient.

Cost can depend on insurance coverage, deductible status, coinsurance or copays, medication benefits, treatment and monitoring benefits, network participation, and eligibility for applicable manufacturer assistance programs.

Benefits verification can provide a more useful estimate based on your specific insurance plan.

An insurance denial does not always mean the process is over.

Depending on the reason for denial and the patient's clinical situation, possible next steps may include supplying additional documentation, addressing missing requirements, requesting reconsideration, or pursuing an appeal when clinically appropriate.

If coverage ultimately cannot be obtained, your clinician can discuss other treatment options.

Yes. Wholesome Clinic provides in-person Spravato treatment at our Frisco, Texas location.

Treatment takes place at:

Spravato dosing itself cannot be completed by telehealth because supervised administration and post-treatment monitoring are required.

The first step is a Spravato consultation and clinical evaluation.

We review your depression history, diagnosis, previous treatments, current medications, medical history, and safety considerations.

If Spravato appears clinically appropriate, the next steps may include benefits verification, prior authorization, obtaining required documentation, treatment scheduling, and preparation instructions.

Schedule a Spravato consultation or learn more on our Spravato Treatment in Frisco page .

Missing a treatment does not automatically mean you must restart the entire program.

If a session is missed during the first four weeks, the prescribing information generally directs patients to continue the current schedule. During maintenance treatment, worsening symptoms after missed sessions may lead the clinician to consider a return to a more frequent schedule.

Contact the clinic if you miss an appointment so your clinician can determine the appropriate schedule for your situation.